#1 Clinical Trials Search in Europe

Argatroban Monohydrate

Clinical trials are studying Argatroban Monohydrate in patients who need ECMO support for severe heart or lung failure. These studies compare it with other anticoagulation strategies to see how well it helps prevent clotting and how safe it is. The main focus is on patients with respiratory failure, circulatory failure, or both.

Table of Contents

Clinical trial overview

The available trials are studying Argatroban Monohydrate in people who need ECMO, which is a machine used for advanced heart and lung support.[1][2] These studies are not general drug information studies; they are focused on whether different anticoagulation strategies can help prevent clotting during ECMO support.[1][2]

Both trials are interventional, which means the research team gives a study treatment and then watches what happens.[1][2] The trials are currently listed as Authorised.[1][2]

Key studies of Argatroban Monohydrate

One study is NCT06442267, titled “Comparing Anticoagulation Strategies using Unfractionated heparin, Argatroban and Low-molecular-weight heparin for Extracorporeal Membrane (CASUAL ECMO).”[1] It is a Phase 3 study with 90 planned participants and compares three anticoagulation options during ECMO: unfractionated heparin, low-molecular-weight heparin, and Argatroban Monohydrate.[1]

The other study is 2025-524553-13-00, titled “Low-dose versus standard-dose anticoagulation with argatroban or enoxaparin during extracorporeal membrane oxygenation controlled by anti-IIa or anti-Xa assay.”[2] It is a Phase 2 study with 200 planned participants and compares low-dose and standard-dose anticoagulation with Argatroban Monohydrate or enoxaparin during ECMO.[2]

In the second study, treatment is guided by anti-IIa or anti-Xa testing, which are blood tests used to check the effect of anticoagulation.[2] This helps the researchers compare treatment strategies in a more controlled way.[2]

Who may take part

The first trial includes people with respiratory insufficiency, respiratory failure, circulatory failure, or acute respiratory distress syndrome who need ECMO support.[1] These are serious conditions where the lungs and/or circulation are not working well enough on their own.[1]

The second trial includes patients with lung and/or heart failure who are also receiving ECMO support.[2] The studies are aimed at very sick patients who need this advanced machine support, not at people with mild disease.[1][2]

  • ECMO patients: people whose heart and/or lungs need machine support while they are critically ill.[1][2]
  • Severe lung or heart disease: the main target group in these trials.[1][2]
  • Patients at risk of clotting: people in whom the study treatment may help reduce clot-related problems during ECMO.[1][2]

What the trials measure

The main outcome in the Phase 3 study is the incidence of thromboembolic events during ECMO therapy.[1] This means the researchers count how often blood clots or clot-related blockages happen while the patient is on ECMO.[1]

That outcome includes clinically relevant clot events confirmed by imaging, pulmonary embolism, deep vein thrombosis, intracardiac thrombosis, arterial thromboembolism such as heart attack or cerebral infarction, and the need to exchange the ECMO circuit because of clotting.[1] The study also mentions deep vein thrombosis found during daily routine sonography, which is an ultrasound test.[1]

The Phase 2 study measures the efficacy and safety of anticoagulation with Argatroban Monohydrate and enoxaparin, both alone and in the combined patient group.[2] In simple terms, the researchers want to see how well the treatment works and whether it causes problems that matter in this very sick group of patients.[2]

Trial phases and what they mean

Phase 2 studies usually look at early signs of benefit and safety in a moderate number of patients.[2] The Argatroban Monohydrate Phase 2 study includes 200 people and compares low-dose and standard-dose anticoagulation strategies during ECMO.[2]

Phase 3 studies are later-stage trials that compare treatments in a larger and more definitive way.[1] The Phase 3 CASUAL ECMO study includes 90 people and compares Argatroban Monohydrate with heparin-based options to see which strategy better reduces clot events during ECMO.[1]

Patient-friendly terms

Anticoagulation means treatment to reduce blood clotting.[1][2] In these trials, the goal is to balance clot prevention with safe care during ECMO.[1][2]

Thromboembolic events are clot-related problems that can block blood flow in the lungs, legs, heart, brain, or ECMO circuit.[1] These events are important because they can make critical illness more dangerous.[1]

Sonography is another word for ultrasound, a scan that uses sound waves to look inside the body.[1] In the study, it is used to check for deep vein thrombosis during daily routine care.[1]

ECMO circuit exchange means replacing part of the machine system if clotting starts to block it.[1] This is an important practical outcome because clotting can affect how well ECMO works.[1]

Trial ID Phase Condition studied Status Enrollment
NCT06442267 Phase 3 Respiratory insufficiency, respiratory failure, circulatory failure, acute respiratory distress syndrome Authorised 90
2025-524553-13-00 Phase 2 Lung and/or heart failure Authorised 200

FAQ

  • What are the Argatroban Monohydrate trials trying to find out? They are looking at how well Argatroban Monohydrate helps prevent blood clots during ECMO support. The studies also compare safety and overall effectiveness with other anticoagulation treatments.
  • Who can take part in these studies? The trials are for patients on ECMO with serious lung failure, heart failure, respiratory failure, circulatory failure, or acute respiratory distress syndrome. These are people who need advanced life support because their organs are not working well enough.
  • What trial phases are being used? One study is in Phase 3 and the other is in Phase 2. Phase 2 studies usually look at early signs of safety and effectiveness, while Phase 3 studies compare treatments in a larger group.
  • What conditions are being studied? The studies focus on conditions that require ECMO, including respiratory insufficiency, respiratory failure, circulatory failure, acute respiratory distress syndrome, and lung and/or heart failure. The main concern is clot prevention during ECMO treatment.
  • What outcomes are measured in these trials? The studies measure thromboembolic events, which are blood clots that can block blood flow. They also look at events such as pulmonary embolism, deep vein thrombosis, intracardiac thrombosis, stroke or heart attack caused by clots, and whether the ECMO circuit needs to be changed because of clotting.

Ongoing Clinical Trials on Argatroban Monohydrate

  • Study on Anticoagulation Strategies with Heparin, Enoxaparin, and Argatroban for Patients with Respiratory or Circulatory Failure on ECMO Support

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

  • Comparing low-dose and standard-dose argatroban or enoxaparin to prevent blood clots in patients with heart or lung failure receiving extracorporeal membrane oxygenation.

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Czechia

Glossary

  • ECMO: Extracorporeal membrane oxygenation. This is a machine that supports the heart and/or lungs when they are not working well enough.
  • Anticoagulation: Treatment that helps stop blood from clotting too much.
  • Thromboembolic event: A blood clot that forms and blocks blood flow, which can cause serious problems.
  • Pulmonary embolism: A clot that travels to the lungs and blocks blood flow there.
  • Deep vein thrombosis: A blood clot in a deep vein, usually in the leg.
  • Intracardiac thrombosis: A blood clot that forms inside the heart.
  • Arterial thromboembolism: A clot that blocks an artery and can lead to serious events such as heart attack or stroke.
  • Acute respiratory distress syndrome: A severe lung problem that makes it hard to get enough oxygen into the body.
  • Phase 2: A study stage that looks at early safety and whether a treatment seems to work.
  • Phase 3: A later study stage that compares treatments in larger groups of patients.
  • Enrollment: The number of people planned to join a study.
  • Anti-IIa assay: A blood test used to measure how strong an anticoagulant effect is.

References